Feature | June 22, 2012

FDA Panel Does Not Recommend New ACS Indication for Xarelto

Janssen said it will work with FDA to address issues for its use in acute coronary syndromes

June 22, 2012 — The the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for rivaroxaban (Xarelto).  The drug’s maker, Janssen Research and Development LLC, wants to expand the indication to include the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The FDA recently issued a response letter regarding the drug’s supplemental new drug application (sNDA), which the company is evaluating and said it will address the agency's questions.

Xarelto is approved for three clinical uses in the United States: To reduce the risk of blood clots in the legs and lungs of people who have just had knee replacement surgery, to reduce this risk in people who have just had hip replacement surgery and to reduce the risk of both hemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem. Janssen submitted this sNDA in December 2011 and received a priority review designation from the FDA in February.

Healthcare market research firm Decision Resources recently surveyed U.S. cardiologists and managed care organization (MCO) pharmacy directors. Respondents said reducing the incidence of mortality is the greatest unmet need in post-myocardial infarction and Xarelto is being watched as a possible pharmaceutical solution. 

“Despite the declining rate of deaths due to myocardial infarction and despite the emergence of novel antiplatelet agents and optimal statin therapy, the incidence of mortality remains the attribute that most influences surveyed cardiologists’ prescribing decisions in post-myocardial infarction,” said Decision Resources analyst Conor Walsh, Ph.D. “According to clinical data and thought leaders we interviewed, Bayer/Janssen’s Xarelto has demonstrated the potential to significantly fulfill this unmet need.”

For more information: www.janssenrnd.com

Related Content

statins, heart disease, HOPE-3 trial, intermediate-risk patients, hypertension, ACC.16
News | Pharmaceuticals| April 20, 2016
Lowering cholesterol with statins significantly reduced adverse cardiovascular events in people with average...
News | Heart Failure| April 19, 2016
In one of the largest trials ever conducted of heart failure patients with reduced ejection fraction, the...
cardiac arrest, out-of-hospital, antiarrhythmic drugs, New England Journal of Medicine Study, ACC.16
News | Sudden Cardiac Arrest| April 19, 2016
April 19, 2016 — Researchers have confirmed that certain heart rhythm medications, when given by paramedics to patien
Xarelto, rivaroxaban, PMSS study, ACC 2016, NVAF, atrial fibrillation, stroke
News | Antiplatelet and Anticoagulation Therapies| April 08, 2016
New data from an ongoing post-marketing study confirm the safety profile of Xarelto (rivaroxaban) was generally...
Brilinta, ticagrelor, ACC-AHA guideline, acute coronary syndrome
News | Antiplatelet and Anticoagulation Therapies| April 01, 2016
AstraZeneca confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released...
NOACs, novel oral anticoagulants, VTE treatment, venous thromboembolism, GlobalData
News | Antiplatelet and Anticoagulation Therapies| March 21, 2016
The use of novel oral anticoagulants (NOACs) will see a substantial rise after an initially sluggish uptake and will...
atrial fibrillation patients, high stroke risk, not prescribed medication, JAMA Cardiology study
News | Pharmaceuticals| March 17, 2016
Nearly half of all atrial fibrillation (AF) patients at the highest risk for stroke are not being prescribed blood...
statins, sleep apnea, heart disease risk, CUMC study, Science Translational Medicine
News | Cardiac Diagnostics| February 22, 2016
A new study conducted at Columbia University Medical Center (CUMC) has revealed some of the underlying mechanisms that...
News | Business| February 09, 2016
February 9, 2016 — Cigna has entered into an...
ACC late breakers
News | ACC| February 09, 2016
The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology
Overlay Init